August 23, 2022

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

Ref: Scrip Code: 532296

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Name: GLENMARK

Re: *Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015*

Subject: **Update on the Company's Monroe, North Carolina (USA) Facility**

This is with respect to our communication dated May 20, 2022 regarding the US FDA inspection at Glenmark's Monroe, North Carolina (USA) facility from April 04 to May 19, 2022 and issuance of Form-483 by US FDA with 17 observations.

We wish to inform you that the Company has received a communication from the US FDA indicating the inspection classification as "Official Action Indicated" (OAI). The OAI classification implies inter-alia that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved.

The Company had done a voluntary recall of all its products from this site in August 2021 and since then has not been commercializing any product from this site.

Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest. The Company is committed to maintaining the highest quality and compliant manufacturing standards at all of its facilities across the globe.

This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

HARISH VINAYAK KUBER
Digitally signed by HARISH VINAYAK KUBER
Date: 2022.08.23 20:54:09 +05'30'

Harish Kuber
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd.
Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099
T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com